Citius Oncology (CTOR) Free Cash Flow (2023 - 2026)

Citius Oncology (CTOR) posted quarterly Free Cash Flow of -$3.8 million for Q1 2026, up 47.9% quarter-over-quarter from -$7.4 million in Q4 2025.

Citius Oncology (CTOR) Free Cash Flow (2023 - 2026) Analysis & Trends

Citius Oncology (CTOR) has reported Free Cash Flow for 4 consecutive years, with -$3.8 million the latest figure, recorded in Q1 2026.

In Q1 2026, Free Cash Flow changed N/A year-over-year to -$3.8 million; the TTM figure through Mar 2026 stood at -$11.2 million (down 2955.55% YoY), while the FY2025 annual figure was -$5.5 million, down 4446.59% from the prior year.
Free Cash Flow grew to -$3.8 million in Q1 2026 per CTOR's latest filing, from -$7.4 million in the prior quarter.
Across five years, Free Cash Flow topped out at -$100256.0 in Q2 2023 and bottomed at -$7.4 million in Q4 2025.
Historically, Free Cash Flow has averaged -$1.8 million across 4 years, with a median of -$366106.0 in 2024.
On a YoY basis, Free Cash Flow climbed as much as 13.56% in 2024 and fell as far as 265.17% in 2024.
Citius Oncology's Free Cash Flow stood at -$382527.0 in 2023, then grew by 4.29% to -$366106.0 in 2024, then plunged by 1908.97% to -$7.4 million in 2025, then soared by 47.9% to -$3.8 million in 2026.
Business Quant data shows CTOR's Free Cash Flow at -$3.8 million in Q1 2026, -$7.4 million in Q4 2025, and -$366106.0 in Q2 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Free Cash Flow (Qtr)
1	Haleon	43.83 Bn	42.86 Bn	-	-
2	Teva Pharmaceutical Industries	42.87 Bn	39.22 Bn	2.15 Bn	307.00 Mn
3	Zoetis	31.41 Bn	29.73 Bn	1.05 Bn	538.00 Mn
4	Takeda Pharmaceutical	28.55 Bn	22.75 Bn	5.10 Bn	1.14 Bn
5	United Therapeutics	22.08 Bn	19.42 Bn	683.80 Mn	205.60 Mn
6	Viatris	18.73 Bn	17.84 Bn	1.46 Bn	329.00 Mn
7	Neurocrine Biosciences	15.44 Bn	15.05 Bn	935.80 Mn	128.60 Mn
8	Elanco Animal Health	11.75 Bn	11.22 Bn	798.00 Mn	244.00 Mn
9	Dr Reddys Laboratories	10.11 Bn	9.94 Bn	-	-
10	Citius Oncology	80.25 Mn	80.25 Mn	1.00 Mn	-2.71 Mn

Download Data